Sapio Sciences has appointed Rich Roda as chief financial officer, reinforcing its commitment to scaling global growth through AI-driven innovation in biopharma R&D.

Roda brings more than 20 years of financial leadership across technology, healthcare, and professional services, with experience scaling finance operations for growth-stage and private equity–backed companies. He joins from Tiugo Technologies, an affiliate of PSG, where he served as CFO, overseeing integration and scaling of SDK and API-based software companies. His previous roles include senior finance leadership at SimSpace, EngageSmart, Cengage Learning, HealthEdge, Nuance, Constant Contact, McKinsey & Company, and IBM.

Kevin Cramer, CEO and CTO at Sapio Sciences, said: “The biopharma industry is facing rising R&D costs, increasingly complex data, and pressure to accelerate time-to-market for new therapies. Technology, and especially AI, will be critical to overcoming these hurdles and shaping the future of pharmaceuticals and therapeutics. Appointing Rich as CFO ensures we have the financial leadership to support our global growth goals, while continuing to innovate across Sapio’s AI-native lab informatics platform, like AILN and ELaiN.”

Gordon McCall, COO, added: “Rich has a rare combination of financial discipline and growth-focused leadership. His experience in building finance functions that enable companies to scale efficiently makes him an ideal addition to our executive team as we enter our next phase of growth.”

Roda said: “Sapio’s leadership in R&D and lab AI is reshaping how science gets done. I’m excited to join at such a pivotal moment to help scale the company’s operations and ensure the financial strength that supports sustainable growth. By aligning fiscal discipline with Sapio’s breakthrough AI solutions such as AILN and ELaiN, we can accelerate the impact we deliver for customers worldwide.”

Sapio Sciences provides an AI-native platform integrating LIMS, ELN, and scientific data management in a unified environment. The appointment of Roda strengthens the company’s financial foundation as it continues to expand its global presence and support innovation across the biopharma sector.